Navigation Links
ChartTrends®: Multiple Sclerosis Report Reveals the Latest Approach to the Treatment and Management of MS
Date:11/2/2010

EXTON, Pa., Nov. 2, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. has released a syndicated report focused on the management and treatment of multiple sclerosis (MS) in the US. ChartTrends®: Multiple Sclerosis is an annual publication based on patient level data collected on 1,000 MS patients being treated with disease modifying agents (DMAs).

In addition to helping to define the DMA-treated MS patient (demographics, co-morbidities, concomitant medications, prevalence of symptoms and symptomatic treatment), the report provides insight into the factors that drive decisions to initiate treatment and factors that drive DMA brand selection for both first line and switch patients. Profiles for patients treated with each DMA brand (Avonex, Betaseron, Copaxone, Rebif and Tysabri) are provided. There are a number of differences between patients treated with the various DMAs including MRI status, functioning, disease progression, clinical response and likelihood of switching to a pipeline DMA in the future. The most likely patient types for newly approved Gilenya and late-stage DMAs in development (e.g. Movectro, alemtuzumab, daclizumab) are identified. A number of patient characteristics, including disease classification and current DMA brand, influence the likelihood of a potential switch to Gilenya.

Since initiating on their most current DMA, one-third of patients have experienced an exacerbation with the most common symptoms including muscle weakness and gait/coordination issues. While most exacerbations are treated with short steroid pulses, the use of chronic pharmacological treatment is common for management of spasticity, pain syndromes, bladder/bowel dysfunction, depression/apathy and fatigue. The patient types being selected for treatment with Ampyra, the first FDA-approved symptomatic agent for MS launched in March 2010, are identified in the report.

About BioTrends Research Group, Inc.BioTrends Research Group, Inc. provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com. BioTrends Research Group, Inc. is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.For more information, contact:BioTrends Research Group, Inc.Decision Resources, Inc.Sharon Funk

Christopher Comfort404-223-2963

781-993-2597 sfunk@bio-trends.com

ccomfort@dresources.com
'/>"/>

SOURCE BioTrends Research Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Orthopedic Market Research Data Covering Multiple Geographies Released by Millennium Research Group
2. Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis
3. ARIKACE™ Demonstrates Sustained Benefit in Multiple Studies and Over Multiple Cycles of Treatment of Pseudomonas Lung Infections in Cystic Fibrosis Patients
4. UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohns Disease
5. Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients
6. Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets
7. Data from Multiple Clinical Trials of OrbusNeichs Genous™ Bio-engineered R Stent™ Demonstrate Safety and Effectiveness Across Challenging Patient Subsets as Presented at TCT 2010
8. Reportlinker Adds Multiple Sclerosis (MS) Drugs and Biologics: Technologies and Global Markets
9. For Multiple Myeloma Treatment, More Surveyed European Clinicians Consider the Combination of Immunomodulatory Agents and Proteasome Inhibitors Promising With Respect to Efficacy Than Any Other Drug Regimen Combinations
10. The ASCO Post Publishes Multiple Perspectives on Outcome of ODAC Meeting Regarding Bevacizumab in Advanced Breast Cancer
11. Luminex Donates Companys First MAGPIX Multiplexing System to Papua New Guinea Institute of Medical Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... May 5, 2016  Diagnostic imaging has been ... to concerns that these tests cause health care costs to ... imaging, as well as the adoption of new ... medical peripherals that help health care providers cut costs, while ... medical imaging is a renowned authorized reseller of the ...
(Date:5/5/2016)... 5, 2016 Research ... "Europe Thalassaemia Market and Competitive Landscape Highlights ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... and Competitive Landscape Highlights - 2016, provides ... epidemiology, Thalassaemia market valuations and forecast, Thalassaemia ...
(Date:5/4/2016)... NESS ZIONA, Israel , May ... BVXV, TASE: BVXV) announced today that BiondVax,s CEO, Dr. ... 2016 conference in New York City . ... presenting at 10:30am at Pioneers 2016, a conference presented by ... New York Palace Hotel. The BiondVax presentation that ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... May 06, 2016 , ... This Mother’s Day kicks ... everywhere. The 17th annual National Women’s Health Week takes place May 8-May ... Health are combining forces to empower women to make their health a top priority. ...
(Date:5/5/2016)... ... May 05, 2016 , ... While the practice and profession of Aging Life ... aging population has on communities and resources. Aging Life Care plays an important role ... challenges. , Aging Life Care is a holistic, client-centered approach to caring for ...
(Date:5/5/2016)... , ... May 05, 2016 , ... Einstein Medical ... Twitter feed to cover the latest news and commentary at the 2016 ASCRS/ASOA Symposium ... meeting of the American Society of Cataract and Refractive Surgery and the American Society ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... ultraviolet light A (UV-A) for photosynthesis, researchers Juntian Xu and Kunshan Gao tested ... seaweeds. The pair observed that when photosynthetically active radiation (i.e. the white light ...
(Date:5/5/2016)... ... May 05, 2016 , ... Every year 220 Mississippi kids ... of these children. The wishes provide hope and motivation through positive experiences ... Make-A-Wish Mississippi, Brent Wilson said, “In 2016, the organization will grant 50% of ...
Breaking Medicine News(10 mins):